Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer

Abstract

Treatment options for patients with metastatic urothelial carcinoma ineligible for cisplatin-based chemotherapy have historically been limited. O'Donnell etal. recently reported the results of EV-103 Cohort K,1 leading to accelerated approval of enfortumab vedotin and pembrolizumab for cisplatin-ineligible patients and raising additional questions of how to best utilize this effective regimen.